Dr. Mahta Samizadeh is an internationally educated pharmaceutical scientist and pharmacist, with nearly ten years of experience in designing polymeric drug delivery systems and performing physicochemical, biological and efficacy characterization, and expertise in mucosal immunity and inflammation. Before joining Shepherd Therapeutics, she was a postdoctoral fellow at Tufts University. Her expertise lies in designing polymeric nanocarriers for targeted delivery of small molecule drugs as well as mapping pathways associated with mucosal immunity and inflammation.
Dr. Samizadeh’s former areas of experience include the intense study of anti-inflammatory gene and protein expression in acute and chronic mouse models of Chaga’s disease. She also assisted with drug/target development for mouse models of Sjögren’s disease, in collaboration with Biogen as well as with the Forsyth Institute on phase 1 clinical trial sample processes and analysis to study the pattern of changes in saliva in patients with Sjögren’s syndrome.
Dr. Samizadeh received her PhD in Pharmaceutical Sciences from Rutgers University.